EDGAR Filing Documents for 0001867096-23-000151

Form 4 - Statement of changes in beneficial ownership of securities:

SEC Accession No. 0001867096-23-000151

Filing Date

2023-11-21

Accepted

2023-11-21 16:20:16

Documents

Period of Report

2023-11-20

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 4	wk-form4_1700601584.html	4
1	FORM 4	wk-form4_1700601584.xml	4	4156
	Complete submission text file	0001867096-23-000151.txt		5512

Mailing Address C/O XERIS PHARMACEUTICALS 180 N. LASALLE ST., STE. 1800 CHICAGO IL 60601

Business Address

Type: 4 | Act: 34 | File No.: 001-40880 | Film No.: 231428385

Mailing Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607

Business Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 844-445-5704

Xeris Biopharma Holdings, Inc. (Issuer) CIK: 0001867096 (see all company filings)

IRS No.: 871082097 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations